RxDoctor Payments Data

Vlad Dimitriu, MD

Pulmonary Disease · Topeka, KSNPI 1730393000

Payments from drug & device makers

$214in general payments, 2019–2025

Across 15 payments — averaging $14.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$110
  • Mylan Specialty L.p.$27
  • Jazz Pharmaceuticals Inc.$20
  • CSL Behring$16
  • AstraZeneca$15
  • Boehringer Ingelheim$15
  • plus $11 from 1 others

What the payments were for

  • Food & beverage$19993%
  • Education$157%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$214 in reported general payments places this provider in the 15th percentile of 92 pulmonary disease providers in Kansas.

See all pulmonary disease providers in Kansas

Medicare billing

Part B allowed, 2024
$329,831
Medicare patients
1,072
Services billed
2,834

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter488$331,137
AdempasRiociguat17$237,025
Bosentan23$143,089
NucalaMepolizumab15$128,407
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr109$60,375
Breo ElliptaFluticasone/Vilanterol87$41,306
Spiriva HandihalerTiotropium Bromide31$30,814
Spiriva RespimatTiotropium Bromide28$20,182
Advair HfaFluticasone Propion/Salmeterol41$17,827
Breztri AerosphereBudesonide/Glycopyr/Formoterol22$16,941
Stiolto RespimatTiotropium Br/Olodaterol Hcl31$16,827
Incruse ElliptaUmeclidinium Bromide38$16,595
Combivent RespimatIpratropium/Albuterol Sulfate12$15,410
Fluticasone-SalmeterolFluticasone Propion/Salmeterol41$7,243
DuleraMometasone/Formoterol19$6,058

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Nucala, Anoro Ellipta, Breo Ellipta, Incruse Ellipta$110$580,767751 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat, Combivent Respimat$15$52,41871 claims
AstraZenecaBreztri Aerosphere, Symbicort$15$20,46936 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 92 pulmonary disease providers in Kansas.

Other pulmonary disease in Topeka

See the full list for Kansas

Where these figures come from

Is this you, or does something look wrong? →